Annuncio • Mar 11
Red Light Holland Corp. (CNSX:TRIP) entered into a definitive arrangement agreement to acquire Filament Health Corp. (OTCPK:FLHL.F) for CAD 2.8 million. Red Light Holland Corp. (CNSX:TRIP) entered into a definitive arrangement agreement to acquire Filament Health Corp. (OTCPK:FLHL.F) for CAD 2.8 million on March 10, 2026. Under the terms of the Arrangement Agreement, each outstanding common share of Filament will be exchanged for Consideration Shares of Red Light, based on an exchange ratio to be determined in accordance with the Arrangement Agreement, at a deemed price per Consideration Share equal to the greater of: (i) CAD 0.02 (the "Floor Price"); (ii) the ten-day VWAP of Red Light shares ending five business days prior to the Effective Date, and (iii) the ten-day VWAP of Red Light shares commencing the first full business day following the public announcement of the Arrangement Agreement, subject to applicable law and policies of the CSE (the "Consideration Share Price"). In case of termination of transaction, parties will pay a termination fee of CAD 0.50 million.
The transaction is subject to subject to court approval, approval by regulatory board / committee, approval of merger agreement by target board, approval of offer by acquirer board and approval of offer by target shareholders. The deal has been unanimously approved by the board. The expected completion of the transaction is second quarter of 2026.
Evans & Evans, Inc. acted as fairness opinion provider for Filament Health Corp. Annuncio • Jul 31
Filament Health Corp. Announces First-Ever Compassionate Use Approval for Psilocybin in the European Union Filament Health Corp. announced the first-ever approval for compassionate use of psilocybin in the European Union (EU). The Company's botanical psilocybin drug candidate, PEX010, has been authorized for administration to a patient suffering from treatment-resistant depression (TRD) in Germany. The approval was granted under Germany's compassionate use framework and marks the first time psilocybin will be prescribed outside of a clinical trial in the EU. The treatment will be conducted by Dr. Gerhard Grunder at the Central Institute of Mental Health, Department of Molecular Neuroimaging. Annuncio • Jul 07
Filament Health Corp. Announces FDA Authorization of Phase 2 Clinical Trial Studyuating Psilocybin for ALCOHOL Use Discovery in Veterans and First Responders Filament Health Corp. announced that the U.S. Food and Drug Administration (FDA) has authorized a phase 2 clinical trial studying the Company's botanical psilocybin drug candidate, PEX010, for the treatment of alcohol use disorder (AUD) and post-traumatic stress disorder (PTSD) in military veterans and first responders. The trial will be led by Dr. Nathan Sackett at the University of Washington School of Medicine'sCenter for Novel Therapeutics in Addiction Psychiatry. It will be the first clinical trial to study the safety of psilocybin combined with psychological support for the treatment of individuals with both AUD and PTSD. Military veterans and first responders experience some of the highest rates of co-occurring AUD and PTSD, yet treatment options remain limited and are often ineffective. While psychedelic-assisted therapies have shown promise for each condition individually, no prior trials have evaluated the use of psilocybin for both currently. Annuncio • Jun 19
Filament Health Corp. Enters into Exclusive License Agreement with University of Alabama at Birmingham for Data from a Clinical Trial of Psilocybin for the Treatment ofocaine Use Disorder Filament Health Corp. announced that it has entered into an exclusive global license agreement with the University of Alabama at Birmingham (UAB) for intellectual property related to a recently completed Phase 2 placebo-controlled clinical trial of psilocybin as a treatment for cocaine use disorder (CUD). The study investigated the safety and efficacy of a single-dose of psilocybin compared to placebo comparator in 40 adult patients with severe CUD. The trial was led by Principal Investigator Peter Hendricks, Ph.D., University Professor and Heersink Endowed Chair of Psychiatry at the UAB Department of Psychiatry and Behavioral Neurobiology, and a globally recognized expert in psychedelic-assisted therapies for addiction. Filament has obtained rights to access and use the data, know-how, and associated intellectual property from the clinical study, in furtherance of the Company's own proprietary development programs in stimulant use disorders. The partnership will also enable Dr. Hendricks to serve as an advisor to Filament Health and to advance research into other substance use conditions. Annuncio • Jun 11
Filament Health Corp Announces Authorization of Phase 2 Clinical Trial Studying Botanical Psilocybin for Prolonged Grief Disorder Filament Health Corp. announced that the Swedish Ethical Review Authority and the Swedish Medical Products Agency have authorized a double-blind phase 2 clinical trial studying its botanical psilocybin drug candidate, PEX010, at Linkoping University. The trial will be the first to study the effects of psilocybin in the treatment of prolonged grief disorder. People with prolonged grief disorder are at a 20 percent increased mortality risk. Previous psychological research suggests that the loss of a close person affects self-identity, an aspect of the higher cognitive self. Psilocybin is suggested to cause a transient shift from reliance on prior experiences towards current sensations. The clinical trial at Linkoping University will utilize this shift combined with a self-touch intervention to support re-learning about the bodily self in a trial population of 120 individuals. The trial at Linkoping University is expected to begin dosing in Third Quarter 2025. PEX010 is authorized for investigation in 52 clinical trials worldwide for 14 mental health indications. Annuncio • Apr 10
Filament Health Corp. announced that it has received CAD 0.96 million in funding from Negev Capital On April 9, 2025, Filament Health Corp. closed the transaction. The company issued a unit comprise of a secured convertible debenture and a warrant for the purchase of common shares of the company for the gross proceeds of up to CAD 960,000. Annuncio • Apr 09
Filament Health Corp. Announces FDA Authorization of Phase 2 Clinical Trial Studying PEX010, the Company's Biological Psychedelocybin Drug Drug Candidate, in Opioid Use Disorder Filament Health Corp. announced that the United States Food and Drug Administration (FDA) has authorized a phase 2 clinical trial study of its lead drug candidate, PEX010, at the University of Pennsylvania. The trial will study the effects of psychedelic-assisted psychotherapy (PAP) in the treatment of opioid use disorder (OUD), and is funded by the Wellcome Leap, a non-profit organization focused on accelerating breakthroughs in human health, as part of its Untangling Addiction Program. Escalating cases of OUD worldwide emphasize a critical need for the development of innovative treatments that address associated challenges, including neurocognitive difficulties and poor clinical outcomes such as relapse and non-adherence to life-saving opioid medications. Preliminary findings with PEX010 in alcohol use disorder have encouraged testing in the opioid domain, where overdose deaths in the US exceed 80,000 per year. The studies with PEX010 in OUD will be an important initial step in determining the medication's promise in addressing the opioid crisis. The clinical trial at the University of Pennsylvania will focus on the impact of PEX010 on clinical outcomes, with additional measures (e.g., neurocognition) to help predict which patients may be most likely to benefit from this treatment option. The trial at the University of Pennsylvania is expected to begin dosing in by third quarter 2025. PEX010 is authorized for investigation in 51 clinical trials worldwide for 14 mental health indications. Annuncio • Mar 18
Filament Health Corp. Announces Positive Data from Phase 2 Study of PEX010 in Patients with ALCOHOL Use Disorder Filament Health Corp. announced positive data from an open-label phase 2 clinical trial studying the effects of its botanical psilocybin drug candidate, PEX010, for the treatment of alcohol use disorder (AUD) at Psychiatric Centre Copenhagen. The results were published in the Journal of Psychopharmacology and found that a single 25mg dose of PEX010 was safe and effective in reducing alcohol consumption in AUD patients. The open-label phase 2 study investigated single-dose psilocybin therapy in 10 treatment-seeking adults with severe AUD. The treatment involved two preparation sessions, a high-dose psilocybin session (25 mg), and two integration sessions. Alcohol consumption significantly decreased over the 12 weeks following the administration of PEX010. The percentage of heavy drinking days was reduced from 53.6% before receiving PEX010 to 16.1% at week 12 and drinks per day decreased by an average of 3.4 drinks over the 12-week follow up period. This was corroborated by reports of rapid and sustained reductions in craving and temptation and significant increases in self-efficacy. All participants completed the therapy course, and the safety profile was favourable with no serious adverse events. PEX010 is authorized for investigation in 51 clinical trials worldwide for 14 mental health indications. Annuncio • Jan 22
Filament Health Announces Shipment of Botanical Psilocybin to the University of Wisconsin-Madison Filament Health Corp. announced that it has shipped its botanical psilocybin drug candidate, PEX010, to the University of Wisconsin–Madison (UW–Madison) for investigation in two clinical trials. Both trials are United States Food and Drug Administration (FDA)-authorized and will study the effects of psilocybin on neuroplasticity. Research has shown that psilocybin can improve neuroplasticity — the brain's ability to reorganize and form new neural connections — which may contribute to psilocybin's therapeutic effects. At UW–Madison, the first clinical trial studying PEX010, titled The ENHANCE Study, is being funded by the Tiny Blue Dot Foundation. Tiny Blue Dot Foundation is dedicated to advancing scientific research to help individuals understand the concept of Perception Box™, a metaphor, developed by Founder Elizabeth R. Koch which represents the internal beliefs, experiences, and biases that shape how individuals view the world and engage with others. By expanding these boundaries, individuals can reduce suffering, foster greater self-acceptance and empathy for others, and reframe trauma or challenges as opportunities for personal growth. The ENHANCE Study will dose 100 healthy volunteers to examine whether strategies that enhance psychedelic-induced neuroplasticity and increase the long-term salience of the psychedelic experience may also enhance the ability of psychedelics to support long-term enlargement of the Perception Box. The second clinical trial, titled The RECAP2 Study, will examine the proposition that the neuroplastic effects of psychedelics such as psilocybin underlie their long-term effects on wellbeing. This premise will be investigated in a cohort of 60 physically healthy volunteers with slight decline in wellbeing. Both clinical trials at UW–Madison are expected to begin dosing in First Quarter 2025. PEX010 is authorized for investigation in 41 clinical trials worldwide for 14 mental health indications. Annuncio • Jun 14
Filament Health Corp. announced that it has received CAD 1 million in funding from Negev Capital On June 12, 2024, Filament Health Corp. closed the transaction. The common shares issued to Negev and Lightburn pursuant to the financing are subject to a four-month-and-one-day hold period in accordance with applicable securities laws. As a result of the exercise of warrants and the conversion of the note, Negev has become a holder of greater than 20% of the issued and outstanding common shares. The transaction included participation from returning investor Negev Capital Fund One L.P. Fund managed by Negev Capital for 17,284,443 common shares for approximately CAD 900,000. Annuncio • May 06
Filament Health Corp. Announces Change to Board of Directors Filament Health Corp. announced that Chris Wagner has stepped down from his position as Director on the Company's board of directors due to the requirements of a new role, effective April 30, 2024. The Board of Directors and the Company's management team would like to thank Chris for his valuable contributions. Filament CEO Benjamin Lightburn, Dr. Konstantin Adamsky, Jonathan Conlin, and Michael Messinger continue to serve on the Company's board. Annuncio • Feb 15
Filament Health Corp. Completes the First Export of Botanical Psilocybin to Israel Filament Health Corp. announced that it has successfully completed an export of PEX010, the Company's botanical psilocybin drug candidate, to Israel. The shipment is believed to be the first botanical psilocybin to be exported to Israel. Hadassah University Hospital will study PEX010 in a clinical trial examining the effects of psilocybin for treatment-resistant obsessive-compulsive disorder (TR-OCD) and treatment-resistant post-traumatic stress disorder (TR-PTSD). There is little effective therapy for chronic PTSD and despite decades of research, therapeutic options at the chronic stage are mostly limited to rehabilitation and symptom relief, resulting in substantial unmet need for a solution. Preliminary research into psychedelic-assisted psychotherapy for OCD has demonstrated a decrease in symptoms, pointing to the necessity for controlled proof of concept trials to further substantiate its safety and efficacy for TR-OCD. The clinical trial at Hadassah University Hospital is the 28th study globally that is investigating Filament's psilocybin drug candidate for 12 mental health conditions including opioid use disorder, alcohol use disorder, depression, and coma. Filament has supplied PEX010 to clinical trials in Europe, Canada, and the United States, in addition to Israel. Annuncio • Jan 31
Filament Health Announces FDA Opening of Investigational New Drug Application for Substance Use Disorders Filament Health Corp. announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for PEX010, its botanical psilocybin drug candidate, for the treatment of Substance use Disorders (SUD). The IND-opening protocol had previously been submitted to Health Canada and had received no objection from the department. In addition, 24 research institutions and licensing partners in Canada, the USA, Europe, and Israel are studying PEX010 for conditions including alcohol use disorder, depression, and coma. Annuncio • Dec 07
Filament Health Corp. announced that it has received CAD 0.9 million in funding from Negev Capital On December 6, 2023, Filament Health Corp. closed the transaction. The company issued 5,999,998 units for gross proceeds of CAD 900,000. Each warrant entitling the holder thereof to purchase one additional common share until December 5, 2026. Annuncio • Oct 11
Filament Health Announces Health Canada Authorization for Phase 2 Clinical Trial Studying Botanical Psilocybin for Opioid Use Disorder Filament Health Corp. announced Health Canada approval for a phase 2 clinical trial at the University of British Columbia (UBC). The trial will study the effects of PEX010, Filament's botanical psilocybin drug candidate, for the treatment of opioid use disorder (OUD). Standard treatment for OUD is opioid agonist therapy (OAT). But less than half of those who start OAT remain for 6 months, and approximately 1 in 10 patients receiving professional help due to an overdose were receiving OAT. There is a critical need for research into new interventions to support those with OUD, and research indicates that psychedelicassisted therapy may be a promising approach. Annuncio • Oct 01
Filament Health Corp. announced that it expects to receive CAD 2 million in funding from Negev Capital Filament Health Corp. announced a non-brokered private placement to issue minimum of 6,666,667 units and maximum of 13,333,333 units at an issue price of CAD 0.15 for the minimum gross proceeds of CAD 1,000,000.05 and maximum of CAD 1,999,999.95 on September 29, 2023. Each unit will consist of one common share and one common share purchase warrant. Each warrant will be exercisable to acquire one common share for a period of 36 months following the closing date of the offering at an exercise price of CAD 0.20 cents, representing a 33% premium to the issue price, or other amount approved by the Neo Exchange. The transaction was led by returning investor Negev Capital. The transaction is subject to regulatory approval. Annuncio • Sep 26
Filament Health Corp., Annual General Meeting, Nov 07, 2023 Filament Health Corp., Annual General Meeting, Nov 07, 2023. Annuncio • Aug 09
Filament Health Corp. Announces FDA Approval of Two Clinical Trials Studying Its Biological Psychedelic Drug Candidate PEX010 Filament Health Corp. announced approval from the United States Food and Drug Administration (FDA) for two clinical trials at leading American research institutions studying the effects of PEX010, Filament's botanical psilocybin drug candidate, for mental health conditions including cancer-related anxiety and depression. The clinical trial at the University of Washington School of Medicine is studying PEX010 for the treatment of cancer- related anxiety in patients with metastatic cancer. Evidence from a large body of scientific evidence from psychosocial group interventions for cancer patients without psychedelics suggests that the benefits of group therapy plus psilocybin could be substantial. The clinical trial is examining whether the benefits of psilocybin-assisted therapy can be realized in a group model. The trial is underway and has already dosed 5 patients. The clinical trial at theUniversity of California, Los Angeles (UCLA)'s Semel Institute for Neuroscience and Human Behavioral will examine the effects of joining psilocybin treatment with cognitive-behavioural therapy (CBT) for patients with depression. The trial, led by Dr. Marc Weintraub, PhD, Assistant Professor of Psychiatry, will study the combination of the two treatments as it is believed that psilocybin may help facilitate the success of CBT because it encourages greater cognitive flexibility and behavioural motivation. Annuncio • Jul 25
Filament Health Corp. announced that it has received CAD 2.5 million in funding from Negev Capital On July 24, 2023, Filament Health Corp. closed the transaction. The company has issued 27,777,781 units for gross proceeds of CAD 2,500,000. Annuncio • Jan 19
Filament Health Announces Clinical Trial Approval in Partnership with Psychiatric Centre Copenhagen Filament Health Corp. announced the approval of a clinical trial in partnership with Psychiatric Centre Copenhagen. The trial, led by PhD student Mathias Ebbesen Jensen and Professor Anders Fink-Jensen, will study Filament's natural psilocybin drug candidate for the treatment of alcohol use disorder (AUD) and was recently approved by the Danish Medicines Agency. Five percent of all deaths worldwide each year result from the harmful use of alcohol. With this trial, Psychiatric Centre Copenhagen will determine the effects of a single administration of 25 milligrams of psilocybin on alcohol use and study the extent to which the brain is affected by psilocybin. Filament Health produces natural psilocybin, extracted from magic mushrooms. The GMP-released drug candidate has been exported from Filament's Metro Vancouver lab and has arrived at the clinical site in Copenhagen in preparation for the trial's start. This is the third European clinical trial which has been approved to use Filament's natural psilocybin. The trial in Copenhagen will begin next month. 
